EMBC
Embecta Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
3.76
PEG
0.03
P/B
-0.84
P/S
0.49
EV/EBITDA
4.95
DCF Value
$36.00
FCF Yield
39.3%
Div Yield
6.8%
Margins & Returns
Gross Margin
63.7%
Operating Margin
32.1%
Net Margin
12.9%
ROE
-20.9%
ROA
13.4%
ROIC
29.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $261.2M | $44.1M | $0.74 |
| Q4 2025 | $264.0M | $26.4M | $0.45 |
| FY 2025 | $1.08B | $95.4M | $1.62 |
| Q3 2025 | $295.5M | $45.5M | $0.78 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.10
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.